Relief Therapeutics Highlights PKU GOLIKE Findings

Relief Therapeutics announced the release of a Plain Language Summary on PKU GOLIKE®, focusing on its usage for phenylketonuria (PKU) management. This summary, published in Future Rare Diseases, simplifies complex clinical data for broader public understanding. Co-authored by PKU experts and patient associations, the document underscores the benefits of PKU GOLIKE®, a prolonged-release amino acid mix.

The study compared PKU GOLIKE® with standard amino acid formulations, revealing a more natural amino acid absorption that mimics whole foods. This steady absorption is essential for individuals with PKU, aiding in metabolic stability. These summaries aim to enhance patient and caregiver understanding, aligning with Relief's patient-centric approach.